Amarin (AMRN) says the FDA has accepted its supplemental new drug application for Vascepa and...

|About: Amarin Corporation PLC (AMRN)|By:, SA News Editor

Amarin (AMRN) says the FDA has accepted its supplemental new drug application for Vascepa and set a December 20 target date to complete its regulatory review. The company's seeking approval of the the cholesterol-reducing fish-oil pill as an adjunct to diet for the treatment of high triglycerides with mixed dyslipidemia. Shares +6.2% in pre-market trading.